semaglutide muscle mass loss GLP-1 and Loss: Semaglutide, Tirzepatide & Lean Here's what you need to

Clinical evidence from studies like STEP 4 showed that discontinuing semaglutide led to significant weight regain in most participants, suggesting that long-term or indefinite use may be necessary for sustained results

Sodium-glucose transport protein 2 (SGLT2) inhibitors Primary mechanism(s) of action Reduce reabsorption of glucose in the kidneys (renal tubules) by inhibiting sodium-glucose transport protein 2 (SGLT2)

ISSN 1471-0048

event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase

The studies encompassed a range of breathwork styles and measured various biomarkers, including malondialdehyde, superoxide dismutase, glutathione, nitric oxide, vitamin C, and total antioxidant capacity levels

Stem Cell & PRP Institute of L.A